These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803 [No Abstract] [Full Text] [Related]
6. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma. Emile J; Cauquil C; Carpentier D; Routier E; Robert C Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774 [No Abstract] [Full Text] [Related]
7. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249 [TBL] [Abstract][Full Text] [Related]
8. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352 [TBL] [Abstract][Full Text] [Related]
9. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors. Becquart O; Lacotte J; Malissart P; Nadal J; Lesage C; Guillot B; Du Thanh A J Immunother; 2019 Oct; 42(8):309-312. PubMed ID: 31246640 [TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report. Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031 [TBL] [Abstract][Full Text] [Related]
11. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961 [TBL] [Abstract][Full Text] [Related]
12. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. Cooper DS; Meriggioli MN; Bonomi PD; Malik R J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981 [TBL] [Abstract][Full Text] [Related]
18. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192 [No Abstract] [Full Text] [Related]
19. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. Yoshino K; Nakayama T; Ito A; Sato E; Kitano S BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934 [TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Messer A; Drozd B; Glitza IC; Lu H; Patel AB Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]